Mirati Therapeutics Inc. (MRTX)

51.35
NASDAQ : Health Technology
Prev Close 52.40
Day Low/High 49.70 / 52.35
52 Wk Low/High 3.10 / 53.50
Avg Volume 469.30K
Exchange NASDAQ
Shares Outstanding 31.78M
Market Cap 1.67B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

SAN DIEGO, June 7, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 2,750,000 shares of its common stock at a price to the public of $38.

Mirati Therapeutics Announces Proposed Public Offering Of Common Stock

Mirati Therapeutics Announces Proposed Public Offering Of Common Stock

SAN DIEGO, June 6, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock.

Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting

SAN DIEGO, May 31, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced that new data from the ongoing Phase 1b clinical trial of single agent sitravatinib will be presented at the 2018...

MRTX Crosses Above Average Analyst Target

In recent trading, shares of Mirati Therapeutics Inc have crossed above the average analyst 12-month target price of $38.00, changing hands for $39.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials

- Six Partial Responses achieved to date in first 23 evaluable patients receiving the combination of sitravatinib and nivolumab for the treatment of checkpoint inhibitor refractory non-small cell lung cancer

The MRTX Paradox: Analysts Bullish But Forecast -36.59% Fall

The MRTX Paradox: Analysts Bullish But Forecast -36.59% Fall

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Mirati Therapeutics Inc . The average 12-month price target for MRTX — averaging the work of 5 analysts — reveals an average price target of $18.20/share.

The MRTX Paradox: Analysts Bullish But Forecast -32.72% Fall

The MRTX Paradox: Analysts Bullish But Forecast -32.72% Fall

Analyst ratings can sometimes be complicated, and we here at ETF Channel have noticed a bit of a paradox with Mirati Therapeutics Inc . The average 12-month price target for MRTX — averaging the work of 5 analysts — reveals an average price target of $18.20/share.

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Home Depot, Lowe's, The Blackstone Group: 'Mad Money' Lightning Round

Jim Cramer highlights Home Depot, Lowe's, The Blackstone Group, Capital Senior Living, Cypress Semiconductor.

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Jim Cramer says don't be too quick to ascribe today's gains just to tax reform. This rally was roaring well before that. Instead, credit Cisco and Wal-Mart Stores.

MRTX Crosses Above Average Analyst Target

MRTX Crosses Above Average Analyst Target

In recent trading, shares of Mirati Therapeutics Inc have crossed above the average analyst 12-month target price of $15.00, changing hands for $15.55/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

First Week Of November 17th Options Trading For Mirati Therapeutics (MRTX)

First Week Of November 17th Options Trading For Mirati Therapeutics (MRTX)

Investors in Mirati Therapeutics Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRTX options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

Mirati Therapeutics Reaches Analyst Target Price

Mirati Therapeutics Reaches Analyst Target Price

In recent trading, shares of Mirati Therapeutics Inc have crossed above the average analyst 12-month target price of $10.00, changing hands for $11.20/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Mirati Skyrockets On Positive Data - Biotech Movers

Mirati Skyrockets On Positive Data - Biotech Movers

The San Diego firm is scheduled to present positive preliminary data for two clinical studies of sitravatinib in non-small cell lung cancer at a symposium in Chicago on Friday.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies -- including Opko Health and Mirati Therapeutics -- have been scooping up shares of their own stock lately.

Corporate Insiders at These 5 Companies Are Buying Large Sums of Stock

Corporate Insiders at These 5 Companies Are Buying Large Sums of Stock

Here are the names to know.

5 Stocks Under $10 That Could Make You a Lot of Money

5 Stocks Under $10 That Could Make You a Lot of Money

These stocks trading for less than $10 a share are within range of triggering big breakout trades. Here's how to trade them from here.

7 Stocks Under $10 Making Big Up Moves

7 Stocks Under $10 Making Big Up Moves

Here's a technical look at how to trade several under-$10 stocks that were making big moves to the upside recently.

First Week of MRTX August 19th Options Trading

First Week of MRTX August 19th Options Trading

Investors in Mirati Therapeutics Inc saw new options become available this week, for the August 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRTX options chain for the new August 19th contracts and identified one put and one call contract of particular interest.

These 5 Stocks Are Poised for Breakouts

These 5 Stocks Are Poised for Breakouts

These stocks are setting up to trigger big breakout trades. Here's how to trade them from here.

Relative Strength Alert For Mirati Therapeutics

Relative Strength Alert For Mirati Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Mirati Therapeutics Becomes Oversold (MRTX)

Mirati Therapeutics Becomes Oversold (MRTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Commit To Buy Mirati Therapeutics At $17.50, Earn 20.7% Annualized Using Options

Commit To Buy Mirati Therapeutics At $17.50, Earn 20.7% Annualized Using Options

Investors eyeing a purchase of Mirati Therapeutics Inc shares, but cautious about paying the going market price of $21.20/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $17.50 strike, which has a bid at the time of this writing of $2.30.

Mirati Therapeutics Stock Sees Short Interest Decrease By 14%

Mirati Therapeutics Stock Sees Short Interest Decrease By 14%

The most recent short interest data has been released by the NASDAQ for the 03/31/2016 settlement date, which shows a 254,842 share decrease in total short interest for Mirati Therapeutics Inc , to 1,571,517, a decrease of 13.95% since 03/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Mirati Therapeutics is Now Oversold (MRTX)

Mirati Therapeutics is Now Oversold (MRTX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.